Results 201 to 210 of about 33,233,550 (381)

2. Promoter Trapping Reveals Significant Differences in Integration Site Selection between MLV and HIV Vectors [PDF]

open access: hybrid, 2004
Brian C. Beard   +4 more
openalex   +1 more source

Integrative analysis of circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients: a comprehensive approach

open access: yesMolecular Oncology, EarlyView.
This study simultaneously investigated circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients. The elevated expression of JUNB and CXCR4 in CTCs was a poor prognostic factor for SCLC patients, whereas exosomal overexpression of these biomarkers revealed a high discrimination ability of patients from healthy individuals,
Dimitrios Papakonstantinou   +13 more
wiley   +1 more source

Significant Difference of Clinical Manifestations between Smear Negative and Smear Positive Pulmonary Tuberculosis [PDF]

open access: bronze, 2004
Thomas Chang-Yao Tsao   +3 more
openalex   +1 more source

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

open access: yesMolecular Oncology, EarlyView.
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou   +11 more
wiley   +1 more source

Assessing the Frontiers of Ultra-Poverty Reduction: Evidence from CFPR/TUP, an Innovative Program in Bangladesh [PDF]

open access: yes
This paper uses household panel data to provide robust evidence on the effects of BRAC’s Targeting the Ultra-poor Program in Bangladesh. Our identification strategy exploits type-1 errors in assignment, comparing households correctly included with those ...
M. Shahe Emran   +2 more
core  

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

On the notion “significance of the difference”

open access: yesJournal of Physics: Conference Series, 2018
Nikita Okunev   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy